Prognostic study introduces a risk assessment model for hepatocellular carcinoma treated with surgery or chemoembolization, highlighting multidimensional evaluation.
PASTAfter curative resection, the prognosis for hepatocellular carcinoma (HCC) varies greatly, with a 30-70% 5-year survival rate.Likewise, the same can be said for patients with unresectable HCC treated with transarterial chemoembolization (TACE).To more accurately evaluate patient prognosis, several grading systems have been created.Most scoring systems only focus on a few aspects of this complex disease, resulting in a limited prognostic value. 1,2As a result, scoring systems are still not frequently used in clinical practice.Therefore, our goal was to create a scoring system that was simple to use and took into account the three key prognostic factors: liver function, systemic inflammation, and tumor features.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: